A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII by Trembath, Dimitri G et al.
BioMed  Central
Page 1 of 13
(page number not for citation purposes)
Molecular Cancer
Open Access Research
A novel small molecule that selectively inhibits glioblastoma cells 
expressing EGFRvIII
Dimitri G Trembath*1, Anita Lal2, David J Kroll3, Nicholas H Oberlies3 and 
Gregory J Riggins1
Address: 1Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA, 2Brain Tumor Research 
Center, Department of Neurological Surgery, University of California San Francisco, CA 94143, USA and 3Natural Products Laboratory, Research 
Triangle Institute, Research Triangle Park, NC 27709, USA
Email: Dimitri G Trembath* - dtremba1@jhmi.edu; Anita Lal - alal@itsa.ucsf.edu; David J Kroll - kroll@rti.org; 
Nicholas H Oberlies - oberlies@rti.org; Gregory J Riggins - griggin1@jhmi.edu
* Corresponding author    
Abstract
Background: Mutations of the epidermal growth factor receptor (EGFR) are a possible molecular
target for cancer therapy. EGFR is frequently amplified in glioblastomas and 30 to 40% of
glioblastomas also express the deletion mutation EGFRvIII. This frequent oncogenic mutation
provides an opportunity for identifying new anti-glioblastoma therapies. In this study, we sought
small molecule inhibitors specific for cancer cells expressing EGFRvIII, using isogenic parental cells
without EGFRvIII as a control.
Results: A screen of the NCI small molecule diversity set identified one compound, NSC-154829,
which consistently inhibited growth of different human glioblastoma cells expressing EGFRvIII, but
permitted normal growth of matched control cells. NSC-154829 had no previously established
medicinal use, but has a purine-like structural component. Further experiments showed this
compound increased apoptosis in cells with EGFRvIII, and moderately affected the expression of
p21, independent of any changes in p53 levels or in Akt phosphorylation.
Conclusion: These initial results suggest that NSC-154829 or a closely related structure might be
further investigated for its potential as an anti-glioblastoma drug, although its precise molecular
mechanism is still undefined.
Background
The epidermal growth factor receptor (EGFR), a type I
tyrosine kinase receptor, has been associated with numer-
ous malignancies including breast, lung, head and neck,
bladder, colorectal, ovarian, and prostate carcinomas, as
well as with the most common form of brain tumor,
glioblastoma [1]. Several small molecules have been
developed to target EGFR including gefitinib (Iressa) and
erlotinib (Tarceva), which interfere with ATP-binding and
tyrosine kinase activity. EGFR inhibitors have shown
promise and extended patient survival in lung, pancreatic
and other cancers, however, survival gains are often mod-
est, and, in non-small-cell lung cancers, activity is limited
to the approximately 10% of patients with small activat-
ing mutations in the EGFR tyrosine kinase domain [2,3].
It also appears that subsequent mutations at different
amino acids, also in the kinase domain, can confer drug
resistance [4].
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Targeting EGFR in glioblastomas has the additional chal-
lenge of the expression of EGFRvIII (epidermal growth
factor receptor variant type III; also named de2-7 EGFR
and deltaEGFR). EGFRvIII is found in 67% of tumors with
amplified EGFR [5] and reported in 38% of all glioblasto-
mas [6]. There has been recent evidence that EGFRvIII is
also present in a minority (5%) of squamous cell lung
cancers [7]. EGFRvIII is a deletion between exons 2–7 of
the EGFR gene with loss of 267 amino acids from the
extracellular domain, creating a constitutively active ver-
sion of the protein [8]. EGFRvIII exists at high frequency
in glioblastomas, and according to some reports imparts a
worse prognosis and confers therapeutic resistance [9-13].
Our earlier work demonstrated that EGFRvIII expression
in glioblastoma cells increased cellular motility and in
vitro invasiveness [14]. In terms of current EGFR therapies,
the picture in regards to glioblastomas is mixed. The
kinase domain mutations correlated with gefitinib
response are infrequent in glioblastomas and phase II tri-
als of gefitinib showed no survival benefit in glioblastoma
[15,16]. Yet, in a more recent study, tumors with both
EGFRvIII and PTEN mutations responded better to EGFR
inhibitors erlotinib or gefitinib [17]. However, since the
present EGFR inhibitors have, at best, a small survival
benefit in glioblastomas and as their use may select for
further resistance-conferring mutations, there is utility in
identifying additional compounds that can specifically
inhibit cells with the EGFRvIII mutation.
To find new inhibitors of glioblastoma cells expressing
EGFRvIII, we used an isogenic cell-based approach for
screening small molecule libraries [18]. For this study we
stably transfected an established glioblastoma cell line
with EGFRvIII using antibiotic selection. Generally, gliob-
lastoma cell lines lose their native EGFRvIII over time
when passaged in vitro, making it necessary to replace this
oncogene to study it in vitro. The two isogenic cell lines
(with and without EGFRvIII) were transfected with yellow
or blue fluorescent protein respectively, and then these
different fluorescent markers were used to independently
track the growth of the two cell lines. Individual diverse
small molecules were dissolved in the media of different
multititer plate wells, each containing an identical co-cul-
ture of the mutant and control cells. In vitro growth of
each cell line, and its response to the different small mol-
ecules, was monitored by measuring fluorescence levels
over one week. In this manner, compounds that specifi-
cally inhibit the growth of the mutant-containing cell line
were identified (see Figure 1). We applied this isogenic
cell line screening strategy to the National Cancer Insti-
tute's diversity set of 1,990 small molecules to identify
growth inhibitors of EGFRvIII-containing cells.
Results
Identification of NSC-154829
Our primary small molecule screen identified 118 com-
pounds with one of three properties: 1) inhibition of both
cell lines, 2) preferential inhibition of one cell line, or 3)
stimulation of both cell lines. Figure 2a–c shows examples
of non-selective and selective inhibition (b and c respec-
tively) contrasted with an example of non-inhibition (a).
Of the 1,990 compounds, 118 (6%) had an observable
effect on cell growth at 2 μM, a result similar to the 5.7%
reported for the screen of K-Ras inhibitors [18]. These 118
compounds were re-screened at concentrations ranging
from 0.03 to 4 μM to determine if there was a dose-
dependent effect on the EGFRvIII-containing cell line
(Figure 2d–f). In this secondary screen, 36 compounds
inhibited both cell lines across different concentrations,
and of these, 15 demonstrated a preferential inhibition of
the EGFRvIII cell line in the primary screen. Accordingly,
these 15 inhibitory compounds were submitted to a terti-
ary screen, but now against two different subclones of the
897 (control) and 898 (EGFRvIII) cell lines. Seven com-
pounds that did not inhibit all of the 898 subclones were
eliminated. The remaining eight compounds consistently
and preferentially inhibited growth of the 898 cell lines
and did not inhibit growth of the 897 cell lines.
Verification of NSC-154829's selectivity against EGFRvIII + 
cells
To insure that the selectivity against cells expressing
EGFRvIII was not a function of genetic background, two
additional tests were performed on the remaining eight
compounds: 1) the compounds were tested against addi-
tional 897 and 898 subclones (again transfected with blue
and yellow fluorescent protein respectively), to determine
if there were consistent significant difference in IC50s
between the wild type and mutant cells and 2) the com-
pounds were tested against a different glioma cell line,
D54 and D54E, the latter transfected with EGFRvIII. Test-
ing using different 897/898 subclones was performed
using the same fluorescent screen as described earlier. IC50
values for one of the compounds, NSC-154829, are
shown in Table 1; for each set of subclones, there was a
significant lower IC50 for the 898 cells compared to the
897s. For testing the compounds against the D54 and 54E
cell lines, cells were plated in individual wells and treated
with the eight compounds that demonstrated preferential
activity against the 898 cells. Growth was measured using
a SybrGreen fluorescence assay [19]. Using this approach,
NSC-154829 was the sole compound out of the original
1,990 that consistently showed preferential inhibition of
EGFRvIII + cell lines in both the 897/898 and D54/54E
systems. Figure 3 shows the preferential inhibition of one
of the 898 subclones (a), the significant decrease in cell
growth for the D54E cell line at 2 μM (b), and the struc-
ture of NSC-154829 (c). D54E also demonstrated a signif-Molecular Cancer 2007, 6:30 http://www.molecular-cancer.com/content/6/1/30
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Diagram demonstrating the approach to screening small molecule libraries using cell lines that a) differ by a mutation of interest  and b) are transfected with different fluorescent proteins Figure 1
Diagram demonstrating the approach to screening small molecule libraries using cell lines that a) differ by a mutation of interest 
and b) are transfected with different fluorescent proteins. Cells with wild-type EGFR are transfected with blue fluorescent pro-
tein while their mutant counterparts, expressing EGFRvIII, are transfected with yellow fluorescent protein. Equal numbers of 
the transfected cells are co-cultured in the individual wells of a microtiter plate and, if left untreated, produce combined blue 
and yellow fluorescence. Appropriate concentrations of small molecules (1 small molecule per well) are then added and fluo-
rescence levels measured over seven days. Well G10 would be considered a "hit" as the small molecule is reducing the growth 
of the mutant cell line, leaving only a blue fluorescent signal.Molecular Cancer 2007, 6:30 http://www.molecular-cancer.com/content/6/1/30
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icantly lower IC50  when treated with NSC-154829,
compared to D54 (see Table 1).
Examples of EGFRvIII and control cell growth responses to small molecule diversity set compounds Figure 2
Examples of EGFRvIII and control cell growth responses to small molecule diversity set compounds. a) Most compounds 
showed no effect on either cell line. The two matched cell lines with no drugs (red circle = 897 and red square = 898) have a 
growth curve similar to the matched lines grown with a drug (light blue circle = 897, dark blue square = 898). Under normal 
circumstances, the 898 cells with EGFRvIII (square symbols), will eventually overtake the 897 mutant free cells (circle symbols) 
within the wells of the 96 well plate. b) Those compounds with a general toxic effect are apparent because both 897 and 898 
will stop growing in response to drug treatment compared to cells without drug. c) Single inhibition of the 898 mutant cells as 
shown indicates a possible hit on the primary screen. d-f: Example of secondary screen results showing concentration effect on 
EGFRvIII containing cells. d) 4 μM concentration. e) 0.05 μM concentration f) 0.025 μM concentration. Each point represents 
an average of four experiments. Growth curves for mutant containing cells (898) are labeled as follows: dark blue square is 
with compound; red square is without compound. Isogenic cells without EGFRvIII (897) are labeled as follows: light blue circle 
is with compound; red circle is without compound.
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Relative purity of NSC-154829
The relative purity of small molecules from the NCI
library with selective activity against 898 cells was assessed
by HPLC, since degradation is a potential problem in
chemical libraries. NSC-154829 demonstrated 82%
purity, using an area-under-the-curve analysis.
NSC-154829's effects on cell growth
Trypan blue studies were performed on 897 and 898 cells
treated with 2 μM of NSC-154829. The percentage of dead
cells remained similar between treated cell lines versus
controls during the first 24–48 hours following treatment;
however, at 48 hours, the percentage of dead cells present
in the EGFRvIII+ cell line increased dramatically and sig-
nificantly over wild-type (see Figure 4a). Hoechst staining
of treated cells, examined on days 0–3, showed a signifi-
cant increase in the number of apoptotic nuclei in the
EGFRvIII + cells compared to controls (see Figure 4b).
NSC-154829's effects on apoptosis
To verify that the cell death measured in our fluorescence
and trypan blue studies were due to apoptosis, we investi-
gated if treatment with NSC-154829 resulted in an
increase in caspases, important mediators of apoptosis in
mammalian cells [20,21]. As shown in Figure 5a, treat-
ment of 898 subclones with as little as 1 μM of NSC-
154829 increased caspase 3/7 activity 1.5 fold over treat-
ment with the carrier molecule (DMSO) alone. Similar
treatments of the EFGR wild type cell line (897) produced
no detectable difference in caspase levels compared to
controls (Figure 5a). These changes were seen across dif-
ferent 897/898 subclones (data not shown). To insure
that the presence of the fluorescent proteins was not inter-
fering with the caspase assay, similar experiments were
performed with D54 and D54E. Treatment with 1 μM
NSC-154829 produced minimally increased caspase lev-
els in D54E, compared to those in the wild-type cell line
Table 1: IC50data for NSC-154829
NSC Number IC50897/898 clone 1 IC50897/898 clone 2 IC50897/898 clone 3 IC50 D54/54E trial #1 IC50 D54/54E trial #2 IC50 D54/54E trial #3
154829 0.77 (0.71–0.84); 0.56 
(0.51–0.69);
0.63 (0.49–0.81); 0.36 
(0.35–0.38)
0.62 (0.54–0.71); 0.27 
(0.24–0.30);
0.52 (0.43–0.63); 0.36 
(0.27–0.48)
0.66 (0.52–0.84); 0.32 
(0.21–0.5);
0.53 (0.42–0.68); 0.40 
(0.34–0.46)
p = 0.003 p = 0.0009 p < 0.0001 p = 0.02 p = 0.004 p = 0.03
p values represent IC50 comparisons between wild type and EGFRvIII + cells. Initial numbers represent the mean IC50 and 95% confidence intervals for wild type cells (either 
897 or D54), the latter the mean IC50 and 95% confidence intervals for EGFRvIII + cells (either 898 or D54E). Each individual experiment was performed in sextuplicate
a) Initial growth response curve for 897 and 898 treated with NSC-154829 Figure 3
a) Initial growth response curve for 897 and 898 treated with NSC-154829. Growth curves for mutant containing cells (898) 
are labeled as follows: dark blue square, with compound; red square, without compound. Isogenic cells without EGFRvIII (897) 
are labeled as follows: light blue circle, with compound; red circle, without compound. Each point represents an average of 
duplicate experiments. b) Initial screens at 2 μM showing the selective effect of NSC-154829 on D54E cells, demonstrating effi-
cacy across different genetic backgrounds. *** p < 0.0001. Further screening (see Table 1) would demonstrate significantly dif-
ferent IC50s for the D54 and D54E cell lines when treated with NSC-154829. c) Structure of NSC-154829, showing purine 
backbone.
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(Figure 5b). However, 5 μM and 10 μM of NSC-154829
produced corresponding increases in caspase activity in
the EGFRvIII+ cells and minimal, if any, changes in cas-
pase levels in the wild-type cell line (see Figure 5c and 5d).
Thus, the selective inhibition of cell growth in the
EGFRvIII+ cell lines would appear to be due, in part, to
increasing levels of apoptosis in the mutant cell lines.
NSC-154829's effects on phosphorylated Akt (Ser473)
Studies of glioblastomas and EGFR have focused on the
effects EGFRvIII has in up-regulating the PI3K/Akt path-
way as the mechanism behind the tumorigenicity of
EGFRvIII [22,23]. Inhibition of Akt phosphorylation,
whether by Akt kinase inhibitors or anti-sense oligonucle-
otides, has shown promise in limiting tumor growth,
including glioblastomas [24,25]. Thus, we analyzed NSC-
154829's effects the phosphorylation of the serine 473
residue of Akt in our cell lines via Western blot. The 898
cell line shows mildly increased P-Akt levels in normal
conditions (10% serum) and the absence of drug. Treat-
ment with 2 μM of NSC-154829 produced minimal
changes in P-Akt levels in both the wild type and mutant
cells (data not shown).
It has been previously demonstrated that EGFRvIII is nec-
essary for glioma cell proliferation under serum starvation
conditions and that this proliferation is dependent on
PI3K/P-Akt signaling [23,26]. When we subjected our
897/898 cell lines to serum starvation (0.5% serum), P-
Akt levels were up-regulated in both the wild-type and
mutant cell lines (see Figure 6a, lanes 1 and 2). When
treated with NSC-154829, there is a dose-response effect,
with increasing amounts of NSC-154829 (2 μM in Figure
6a, lanes 3 and 4; 5 μM Figure lanes 5 and 6) leading to a
corresponding decrease in expression of P-Akt. When 897
or 898 cells are exposed to EGF (final concentration 100
ng/mL) there is, not surprisingly, increased expression of
P-Akt (Figure 6a, lanes 7 and 8) in both cell lines. Simi-
larly, this increased expression is mildly abrogated by 2
μM of NSC-154829 in both the wild type and mutant cells
(Figure 6a, lanes 9 and 10).
NSC-154829's effects on P-Akt expression in the glioma
cell line D54/54E was more pronounced, but similar in
both cell lines. There was minimal effect on P-Akt expres-
sion under conditions of 10% serum (data not shown).
When the D54/54E cells were stressed, via exposure to
0.5% serum, P-Akt levels increased dramatically and the
increase in P-Akt in both cell lines was decreased by expo-
sure to 2 μM NSC-154829 (data not shown). This effect,
however, was not consistent, with the decrease in P-Akt
often greater in the wild-type cell line versus mutant as
levels of NSC-154829 increased from 2 to 5 μM. Applica-
tion of EGF (100 ng/mL) did not produce as profound an
increase in P-Akt compared to the 897/898 cell lines and,
again, application of NSC-154829 did not consistently
decrease P-Akt expression in the mutant compared to the
wild-type cell line. Given these results, it appears that
a) Trypan blue studies of cell viability following treatment with NSC-154829 Figure 4
a) Trypan blue studies of cell viability following treatment with NSC-154829. Wild-type (897) or mutant (898) cells were plated 
and treated for either 24, 48, or 72 hours with 2 μM of NSC-154829. Cell viabilities remain similar until 72 hours when cell 
death increases dramatically in the 898 cell line compared to similarly treated 897 cells and DMSO-only treated controls. b) 
Hoechst studies for apoptosis following treatment with NSC-154829. D54 and D54E cells were treated with 2 μM NSC-
154829 and then trypsinized, collected and stained with Hoechst 33258 at days 0, 1, 2 and 3. EGFRvIII+ cells showed a consist-
ent and significant increase in the number of apoptotic nuclei compared to wild type.
b a
1 2 3
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
897-DMSO
897- NSC-154829
898-DMSO
898 - NSC-154829
Day
%
 
d
e
a
d
 
c
e
l
l
s
D54 D54E
0
5
10
15
20
25
30
35
Day 0
Day 1
Day 2
Day 3
**
p = 0.005
p = 0.009
**
Cell line
%
 
A
p
o
p
t
o
t
i
c
 
c
e
l
l
sMolecular Cancer 2007, 6:30 http://www.molecular-cancer.com/content/6/1/30
Page 7 of 13
(page number not for citation purposes)
NSC-154829's selective effect on the EGFRvIII+ cells is not
mediated through P-Akt or intermediary signaling mole-
cules between the receptor and P-Akt.
NSC-154829's effects on the p53/p21 pathway
As it did not appear that NSC-154829 was acting selec-
tively through the P-Akt pathway, we next studied the p53
pathway which is also frequently mutated in glioblasto-
mas, particularly in "secondary" glioblastomas, which
develop from low grade astrocytomas (WHO grade II) to
anaplastic astrocytomas (WHO grade III) and finally to
glioblastomas (WHO grade IV) [27]. The increased cas-
pase activity seen in the EGFRvIII+ cells also suggested this
pathway, given p53's role in apoptosis regulation.
a) Effects on caspase 3 and 7 expression in 897 and 878 cells by treatment with 1 μM NSC-154829 Figure 5
a) Effects on caspase 3 and 7 expression in 897 and 878 cells by treatment with 1 μM NSC-154829. Cells were exposed to 1 
μM NSC-154829 and then caspase 3 and 7 levels measured as outlined in the Materials and Methods. Caspase levels were nor-
malized to DMSO-only treated controls and expressed as fold increases. Each experiment was performed three times and each 
time in sextuplicate. There was borderline significance between the increase in caspase 3 and 7 levels in the mutant cells com-
pared to wild type (p = 0.05). b) Effects of 1 μM NSC-154829 on caspase 3 and 7 levels in the D54/54E cell lines. While there 
was an increase in caspase activity in the D54E cells in response to NSC-154829 treatment compared to D54s, this difference 
was not significant. Each experiment was performed three times in sextuplicate. c) Dose-response effect of NSC-154829 on 
levels of caspase 3 and 7 in the D54 and D54E cell lines. Treatment with 5 μM of NSC-154829 nearly doubled levels of caspase 
3 and 7 in both the wild type (D54) and mutant (D54E) cells. d) Treatment with 10 μM of NSC-154829 doubled levels of cas-
pase 3 and 7 in the mutant cells, but had little effect on the wild-type cell line (*** p < 0.0001). Caspase levels for each cell line 
were normalized to DMSO-only treated controls and expressed as fold-change. Each assay was performed three times in sex-
tuplicate.
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For both cell lines there was little or no effect on p53 in
response to 2 μM of NSC-154829, regardless of serum
conditions (Figures 6b and 6c). The response of p21 was
more variable. Figure 6b shows NSC-154829's effect on
p21 in the 897/898 background. In the presence of 10%
serum, there was a minor increase in p21 in the EGFRvIII+
cells when exposed to 2 μM of NSC-154829 (Figure 6b,
lanes 1–4). This small effect was still present when the
cells were stressed under conditions of 0.5% serum (Fig-
ure 6b, lanes 6 and 8). For the wild-type cells, under con-
ditions of 0.5% serum p21 was unchanged in response to
NSC-154829 (Figure 6b, lanes 5 and 7).
In the D54/54E background, levels of p21 decreased in
both cell lines in response to drug treatment under condi-
tions of 10% serum (lanes 1–4, Figure 6c), but increased
in both cell lines, particularly in the EGFRvIII+ cells, when
grown in 0.5% media and then exposed to NSC-154829
(Figure 6c, lanes 5–8). Although p21 levels were either
increased with drug treatment, or were less down-regu-
lated in the mutant cells for the conditions studied, the
effect was likely not large enough to account for the
growth differences observed with NSC-154829 treatment.
Discussion
Glioblastoma multiforme (GBM) is the most common
primary brain tumor with approximately 12,000 new
cases a year in the United States [28]. Despite extensive
research, the prognosis for GBM is poor, with a median
survival of 10 to 12 months [29]. EGFR mutations have
been demonstrated with a high frequency in glioblasto-
mas with the majority of these tumors demonstrating
increased expression of EGFR and a subset showing
expression of the common deletion mutation EGFRvIII
[5,6]. The latter renders these tumors resistant to radiation
and to many of the commonly used tyrosine kinase inhib-
itors [12,30,31]. The prevalence of the EGFRvIII mutation,
however, could prove to be a useful target for glioblasto-
mas and other tumors with this mutation.
In this study, we used the expression of EGFRvIII to find a
small molecule, NSC-154829, from the National Cancer
Institutes Diversity Set, which selectively inhibits glioblas-
toma cells with this mutation, compared to glioblastoma
cells without the mutation. Using a fluorescence-based
screen, we found that NSC-154829 inhibits the growth of
EGFRvIII + cells (898s), with IC50s of .27 to .59 μM com-
pared to .62 to .77 μM for wild-type cells (897s; see Table
1). The activity across different subclones indicates that
the inhibition is not unique merely due to particular
genetic changes in one subclone, but instead may be due
to changes induced by the presence of EGFRvIII. This con-
clusion is also supported by the preferential activity
against EGFRvIII + cells from a different glioblastoma cell
line, D54/54E. Again, IC50s for the EGFRvIII + cells
(D54E) were significantly lower than that of the wild-type
cells (an average of 0.33 μM for D54E compared to 0.57
μM for D54; see Table 1).
Supporting our screening results were trypan blue studies
that showed the mutant cell line experiencing a dramatic
increase in cell death following treatment with NSC-
Western blot showing effect of 2 μM NSC-154829 on expression of phosphorylated Akt (serine 473; P-Akt) in both 897 and  898 cell lines (a), or on expression of p53 and p21 in the 897/898 and D54/54E cell lines under normal conditions (10% serum)  or serum starvation (0.5% serum) Figure 6
Western blot showing effect of 2 μM NSC-154829 on expression of phosphorylated Akt (serine 473; P-Akt) in both 897 and 
898 cell lines (a), or on expression of p53 and p21 in the 897/898 and D54/54E cell lines under normal conditions (10% serum) 
or serum starvation (0.5% serum). a) Lanes 5–6 demonstrate the effect of serum starvation on the expression of P-Akt in both 
cell lines; this increased expression is diminished by treatment with 2 μM NSC-154829 (lanes 7 and 8). b) 897 and 898 cells 
were grown under conditions of either 10% serum (lanes 1–4) or 0.5% serum (lanes 5–8). Under conditions of 10% serum, 
exposure to 2 μM NSC-154829 has minimal effect on expression of p53, except for a mild decrease in the wild-type cells (897) 
under serum starvation conditions (lane 7). p21 expression increases for both the wild-type and mutant cells under both nor-
mal and serum starvation conditions; although the increase appears greater for the mutant cells (compare lanes 2 and 4). c) 
Effects of NSC-154829 on p53 and p21 in the D54 and 54E cell lines. Under conditions of 10% serum, there is minimal effect 
on p53 and a mild decrease in p21 signaling by NSC-154829. Serum starvation (0.5% serum) combined with NSC-154829 treat-
ment produces an increase in p21 in both cell lines, mutant greater than wild-type (compare lanes 6 and 8), but does not 
appear to affect p53 expression.
b a cMolecular Cancer 2007, 6:30 http://www.molecular-cancer.com/content/6/1/30
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154829 (Figure 4a). Hoechst staining and caspase 3/7
studies support that this increase is due to an increase in
apoptosis in the mutant cells lines, an effect not seen in
the wild-type cells (Figures 4b and 5).
Effects on downstream molecules in the EGFR pathway
were not immediately apparent in our studies. Akt has
received extensive attention in the literature as a possible
target for glioblastoma therapy [24,32]. However our
Western blot studies showed non-selective effects on Akt
phosphorylation in both the wild-type and mutant cell
lines (Figure 6a), which implies that NSC-154829's pref-
erence for inducing apoptosis in the EGFRvIII cells is not
mediated through differences in Akt phosphorylation.
NSC-154829's structure is similar to that of other purine
analogue anti-metabolites, including compounds cur-
rently used as chemotherapeutics, such as fludarabine and
cladribine [33,34]. Indeed these two drugs showed similar
selectivity on our isogenic EGFRvIII lines (data not
shown). Previous studies have shown these nucleoside
analogues work, at least in part, by increasing apoptosis
via up-regulation of p53 and/or p21 [35,36]. Our studies
of p53 and p21 show no effect on p53, but show that p21
responds differently in the mutant cells in response to
treatment with NSC-154829. However, there is no evi-
dence for a direct molecular mechanism of action for
NSC-154829 on the p53/p21 pathway and p21's differen-
tial response varies with cell background and serum con-
ditions. This inconsistent effect may be secondary to other
as yet undefined genetic differences between the two gli-
oma cell lines. Overall, our experiments do not clarify the
mechanism of NSC-154829's selective effect against
EGFRvIII + cells and should not be interpreted as advocat-
ing a direct interaction between NSC-154829 and p21.
It is of interest that reports on similar novel purine ana-
logues show different effects on p53 and p21. Rad-
hakrishnan and Gartel (2006) recently identified a novel
transcriptional inhibitor, NSC-188491, which has struc-
tural similarities to NSC-154829. NSC-188491 increased
p53 levels, but repressed p21, hdm2, and survivin [37].
Park et al. (2006), however, found a more typical relation-
ship between p53 and p21 with MCS-C2, a novel cyclin-
dependent kinase inhibitor with structural similarities to
NSC-154829. Treating prostate cancer cells with MCS-C2
induced apoptosis and produced up-regulation of p53
and p21 [38]. Thus, it would appear that the effects of
nucleoside analogues such as NSC-154829 are mediated
perhaps in part through the p53/p21 pathway, but these
can vary, based on structure and/or genetic background of
the cell line involved. Studying NSC-154829's effect on
DNA synthesis and comparing these effects with those of
existing purine analogues would be logical next steps.
Literature on NSC-154829 is minimal, however the 3D
Mind website indicates this small molecule maps to clus-
ter k18.17, a cluster that does not have a specific activity,
but includes agents such as anti-mitotics [39]. Other small
molecules that map to this cluster have vague structural
similarities; none, however, were included in the diversity
set for testing. Of those small molecules that initially
showed selective activity against the 898 cell line, but
which did not selectively inhibit the D54E cells (data not
shown), NSC-321239 and NSC-75140 both had similar
purine-type backbones to that of NSC-154829. NSC-
188491 (map location: cluster k18.13) was included in
our diversity set and showed efficacy against EGFRvIII+
cells in our primary screen, but did not demonstrate a sig-
nificant IC50 difference in the background of D54/54E
(data not shown).
The presence of EGFRvIII induces many other transcript
and protein changes and some of these may be the critical
steps affected by NSC-154829 [14]. The advantage to the
screen described above is that it targets a mutation fre-
quently and almost exclusively found in GBMs, an
approach previous glioma-centered small molecule
screens have not exploited [32,40,41]. However, this work
is preliminary and we acknowledge that this inhibitor is
unlikely to act as a single therapy to overcome EGFR sign-
aling in glioblastomas because 1) drug resistance is a fre-
quent problem with single modality therapy, 2) the EGFR
pathway can be activated at a point downstream of EGFR
in glioblastoma, and 3) glioblastoma cell lines and
xenografts thrive after loss of EGFRvIII. However, it is
important to note that our approach does not find com-
pounds that directly interact with EGFRvIII, but likely tar-
get a downstream gene product induced by EGFRvIII
pathway activation, and could lead to a therapy synergis-
tic with those that inhibit EGFR directly. For future work
it would be useful to test NSC-154829 in combination
with known EGFR inhibitors and/or proven glioblastoma
therapies such as radiation. The latter may be important,
since EGFRvIII is reported to also enhance radiation resist-
ance [12]. In addition, analogues of NSC-154829 should
be tested to determine if its therapeutic index and drug
delivery properties can be improved.
Conclusion
This study helps demonstrate the potential of cell-based
screening to rapidly identify inhibitors of cells with a can-
cer-associated mutation. Although screens using isogenic
cells with and without a mutation do not initially reveal
the inhibitor's direct molecular mechanism, in our case it
is likely that the target is related to EGFRvIII pathway acti-
vation. In theory, screens such as the one described above
may identify compounds that are specific to a cancer-caus-
ing mutation, but at the risk of yielding a lower percentage
of "hits" and ones with highly toxic side effects, comparedMolecular Cancer 2007, 6:30 http://www.molecular-cancer.com/content/6/1/30
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to traditional cell based screens [18]. Given these limita-
tions, determining in vivo efficacy and the maximum tol-
erated doses are the next steps in the investigation of NSC-
154829. Our findings suggest that NSC-154829, or
closely related structures, should be investigated further
for treatment of cancers with EGFR pathway activation.
Methods
Cell lines and plasmids
Blue and yellow fluorescent protein (BFP and YFP, respec-
tively) expression vectors were kind gifts from Bert Vogel-
stein and described previously [18]. The engineering of
U87 and D54 glioblastoma cell lines either expressing
(898, D54E) or not expressing EGFRvIII (897, D54) was
also described previously [14]. Stable transfectants were
created using Transfast™ (Promega, Madison, WI), and
subclones were isolated by puromycin selection. Fluores-
cence measurements were compared between cell lines,
and different clones were chosen based on the expression
of equal levels of either fluorescent signal over time.
Verification of EGFRvIII expression
Comparative EGFRvIII expression in D54E and D54 cells
has previously been described [14]. RNA expression of
EGFRvIII in 898s was verified using RT-PCR and primers
flanking the deletion site. Western blots were performed
on cell lysates of each individual 897 and 898 clone, as
well as lysates from the D54 and D54E cell lines to verify
EGFRvIII protein expression (data not shown).
Screening procedure
The diversity set of 1,990 synthetic compounds, derived
from a larger collection of almost 140,000 compounds,
was obtained with permission from the Developmental
Therapeutics Group of the National Cancer Institute [42].
A mixture of equal amounts of 10,000 cells each of 897
(wild-type EGFR) and 898 (EGFRvIII mutant) transfected
with BFP or YFP, respectively, were cultured in 96 well
plates (200 μL final volume per well) containing Dul-
becco's Modified Eagle's Medium (DMEM) with 10% fetal
calf serum and puromycin (500 ng/mL). Controls con-
sisted of wells without cells to measure background fluo-
rescence. Twenty-four hours later, 2 μM of each
compound in DMSO was added individually to wells in
columns 2–11; wells in column 1 received DMSO only.
Fluorescence was measured before compound addition
and subsequently every 24 hours for 7 days following
compound addition, using a Genios system (Tecan Instru-
ments, Research Triangle Park, North Carolina). Absorp-
tion/emission spectra for the two fluorescent proteins
were 390 nm absorption/510 nm emission for BFP and
530 nm absorption/590 nm emission for YFP. This pri-
mary screen was performed in duplicate in independent
experiments. Fluorescence data were exported into Graph-
Pad Prism®, Version 4 (San Diego, CA) and growth curves
were plotted. Secondary screens were performed on com-
pounds that demonstrated selective inhibition, using con-
centrations ranging from 0.03 to 4 μM. Tertiary screens
were performed with compounds at 2 μM concentration
against two new additional subclones containing the blue
or yellow fluorescent proteins. Both the secondary and
tertiary screens were performed in four independent runs
and used to calculate the mean and standard error of the
mean for each daily fluorescence level.
For experiments with D54 and D54E, 3,000 cells from
each cell line were plated in individual wells of a 96 well
plate (Day 0). The next day (Day 1), the cells were treated
with either DMSO (Hybrimax™, Sigma-Aldrich, St. Louis,
MO) or with 2 μM of the small molecule of interest. On
Day 4, the media was removed, the cells were lysed with
50 μL of 0.2%SDS, incubated at 37°C for two hours, then
150 μL of a 1:750 solution of SYBR Green I nucleic acid
stain (Molecular Probes, Eugene, OR) added. Fluores-
cence was measured on a Perkin Elmer Wallac 1420 Mul-
tilabel counter (Perkin Elmer, Turku, Finland) with a 485
nm excitation filter and a 535 nm emission filter.
Statistical analyses
Fluorescence levels were measured daily and results aver-
aged for each day, including standard error of the mean.
Growth curves were plotted and compared between each
cell line with and without drug. Linear regression analysis
was used to identify differences between 897 and 898 cell
line growth curves in response to compound treatment,
compared to the DMSO-only treated controls, using a p-
value < 0.05 as the criteria for significance. IC50 values
were determined by comparing fluorescence values for the
898 or 897 cell lines with drug to 898 or 897 without drug
respectively, then transforming and normalizing the data
using GraphPad Prism.
For experiments with D54 and D54E cells, fluorescence
levels were measured on day 4 post drug addition and
results averaged to give a mean and standard error of the
mean. A non-paired T-test was performed to identify dif-
ferences in fluorescent levels between DMSO-only and
compound-treated cells with p-values < 0.05 considered
significant. Outliers were excluded using Grubbs' test.
Compound purity
The relative purities of six of the eight compounds identi-
fied as hits were assessed by HPLC (Waters 600E multisol-
vent delivery system, Milford, MA; HP Chemstation, Palo
Alto, CA) as measured via an evaporative light-scattering
detector (ELSD; S.E.D.E.R.E., Alfortville, France), as this
technology does not depend on a UV-active chromo-
phore. The other two compounds, NSC-73300 and NSC-
609699, were not available in sufficient amounts for this
test and omitted. All analyses of 30 min utilized an InertsilMolecular Cancer 2007, 6:30 http://www.molecular-cancer.com/content/6/1/30
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ODS 3 column (5 μm, 4.6 × 250 mm; MetaChem Tech-
nologies, Torrence, CA). As each compound had slightly
different chromatographic properties, individualized
mobile phases of varying concentrations of HPLC-grade
MeOH and H2O were developed, and the latter had either
trifluoroacetic acid (TFA) or triethylamine (TEA) added as
modifiers to enhance the chromatographic separations.
Using an isocratic system 80:20 MeOH:H2O (0.1%TFA),
NSC-177407 dissolved in MeOH had a Rt of 14.2 min.
Using an isocratic system of 20:80 MeOH:H2O
(0.1%TFA), NSC-75140 dissolved in MeOH had a Rt of
5.6 min. Using a gradient system of MeOH:H2O
(0.1%TFA) that ramped from 20:80 to 80:20 over 30 min,
NSC-154829 dissolved in H2O had a Rt of 10.9 min, and
using the same system, NSC-321239 dissolved in DMSO
had a Rt  of 14.3 min. Using a gradient system of
MeOH:H2O (0.1%TFA) that ramped from 20:80 to 80:20
over 20 min and was then held isocratic thereafter, NSC-
163443 dissolved in DMSO had a Rt of 23.7 min. Using an
isocratic system of 40:60 MeOH:H2O (0.05% TEA), NSC-
100880 had a Rt of 5.0 min.
Trypan blue studies
100,000 cells from each cell line were plated individually
and allowed to grow for 24 hours. NSC-154829 was
added at a final concentration of 2 μM and cells washed,
trypsinized, and collected at appropriate time points (24,
48, or 72 hours). The collected cells were mixed with
trypan blue (Sigma-Aldrich, St. Louis, MO) and cell
counts performed. 300 cells were counted for each exper-
iment and each experiment was performed in duplicate.
Hoechst studies
100,000 cells from each cell line were plated individually
and allowed to grow for the specified time periods. NSC-
154829 was added at a final concentration of 2 μM and
then cells were washed, trypsinized, and collected at
appropriate time points. The cells were resuspended in 40
μL of Hank's Balanced Salt Solution (Invitrogen,
Carlsbad, CA, U.S.A.) and then mixed with 360 μL of
Hoechst solution (300 μl PBS, 20 μl 10% NP-40, 36 μl
37% formaldehyde and 4 μl 1 mg/ml Hoechst 33258
[Invitrogen, Carlsbad, CA, U.S.A.]). A minimum of 300
nuclei were then evaluated using fluorescent microscopy.
Each time point was evaluated in triplicate and increases
in number of apoptotic nuclei were evaluated using a stu-
dent's T-test.
Apoptosis assays
Apoptosis assays were performed using the Caspase-Glo®
3/7 Assay (Promega Corporation, Madison, WI, U.S.A.)
according to manufacturer's instructions. Briefly, 5,000
cells were plated in 100 μL media and allowed to grow for
24 hours. NSC-154829 was then added at an appropriate
final concentration (1, 2, 5, or 10 μM). Cells were treated
for 24 hours, and then the plates removed from the incu-
bator and allowed to equilibrate to room temperature.
100 μL of Caspase-Glo® 3/7 reagent was added to each
well, the contents mixed, and then the plate incubated for
1 hour at room temperature. Luminescence was measured
on a Perkin Elmer Wallac 1420 Multilabel counter (Perkin
Elmer, Turku, Finland) per manufacturer instructions.
Luminescence levels of NSC-154829 treated wells were
normalized to DMSO-treated controls and fold increases
in caspase 3/7 levels compared using student's T-test.
Western blotting
40,000 cells were plated in individual wells of six-well tis-
sue culture plates, allowed to grow overnight, and then
treated with either DMSO or appropriate concentrations
of NSC-154829 (2, 5 or 10 μM) for 24 or 96 hours. Media
was removed, the cells were washed with 1x PBS,
trypsinized, and collected. Cells were lysed and protein
collected using Pierce NE-PER® Nuclear and Cytoplasmic
Extraction Reagents (Rockford, IL, U.S.A.), following
manufacturer's instructions. Protein extracts were quanti-
fied using the Pierce BCA™ Protein Assay Kit. Equal
amounts were loaded onto NuPage® Novex 4–12% Bis-
Tris gels (Invitrogen, Carlsbad, CA, U.S.A.) and electro-
phoresed for 1.5–2 hours at 80 volts. Proteins were trans-
ferred to Immunoblot PVDF membranes (Bio-Rad,
Hercules, CA, U.S.A.), then probed with antibodies
against phosphorylated Akt, EGFR, p53, p21 (Cell Signal-
ing Technology, Danvers, MA, U.S.A), GAPDH (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, U.S.A), or neu-
ron specific beta-III tubulin (R&D Systems, Minneapolis,
MN, U.S.A.). Appropriate horseradish peroxidase-conju-
gated secondary antibodies and the ECL Plus (GE Health-
care Bio-Sciences Corp., Piscataway, NJ, U.S.A.) were used
for chemiluminescent detection. Following application of
the chemiluminescent substrate, blots were exposed to
Hyperfilm ECL (GE Healthcare Bio-Sciences Corp., Piscat-
away, NJ, U.S.A.) for appropriate periods of time.
For experiments involving serum starvation, appropriate
numbers of cells were initially plated in media with 10%
serum, allowed to grow for 24 hours, then the media
removed; the cells were washed, and then maintained in
media with 0.5% serum for the duration of the experi-
ments. Cells stimulated with EGF were exposed to 100 ng/
mL of EGF for 15 minutes and then cells were collected,
lysed, and protein extracted as described above.
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